Strides Expects Bhami Tech To Boost CDMO Arm; Former CFO Now MD And Group CEO
“We Are Very Late” With Teriparatide Launch
Strides expects a licensing of Bhami’s formulation technology that enables subcutaneous delivery of biologics to boost associate company OneSource’s CDMO business. Meanwhile, its former CFO has been appointed MD and group CEO amid a US portfolio re-balance
